Found "Pharmaceuticals": 23 results
Sort by
Relevance

Development of health technology assessment management

The Health Intervention and Technology Assessment Program (HITAP) was established in 2007 as a non-profit organization. Its main responsibility is to assess health interventions and technology assessment with the coverage of pharmaceuticals, medical devices, interventions, individual and community health promotions and disease prevention, as well a

A Determination of Topics for Health Technology Assessment in Thailand: Case Study for Decision Makers Participation (2007-2008) (in Thai language)

An aim of this study is to describe quantitatively and qualitatively progression and findings from the HTA topic selection process recently developed by HITAP. The process involves potential users of HTA information; namely (1) third party payers (public health insurers), (2) national health care program managers (Ministry of Public Health’s Depa

Assessing the implications of Thailand’s government use licenses, issued in 2006-2008

This study aims to assess the impact of the compulsory licensing (CL ) policy issued by Thailand’s Ministry of Public Health during December 2006 to January 2008 on antiretroviral drugs - efavirenz and lopinavir/ritonavir combination, an oral antiplatelet agent - clopidogrel, and four anti-cancer drugs - imatinib, erlotinib, letrozole, and doceta

Health Technology Assessment Development in Bhutan

Bhutan\'s Ministry of Health, especially the Essential Medicine and Technology Division (EMTD), is one of HITAP\'s long-term partners. From 2018 to 2019, HITAP with PATH supported Bhutan to conduct an economic evaluation for the implementation of a national program for rotavirus vaccination. HITAP also provided and continues to find opportunities f

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. (2013)

Balancing the right to know and the privacy of the patent system: a case study of oncology medicines in Thailand. Inthira Yamabhai; Richard D. Smith Abstract: This study aims to illustrate the processes to determine medicine patent status in developing countries by using oncology medicine in T

FDA approves Ironwood constipation drug

The drug, linaclotide, will be sold under the brand name Linzess and carry a boxed warning that it should not be used in patients 16 or younger, the agency said.An estimated 63 million people suffer from chronic constipation, according to the National Institutes of Health. Additionally, an estimated

How can chatbots address vaccine hesitancy? A study from Asia explores

Vaccines have been a game-changer in the fight against COVID-19. Yet, vaccine hesitancy has impeded its uptake, impacting public health efforts. At the outset of the pandemic, people had doubts about this unfamiliar virus and subsequently, the vaccine: misinformation, rumours, and doubts about COVID

After Delay, OxyContin’s Use in Young Is Under Study

To learn how best to prescribe powerful drugs to children, Congress passed a law in the 1990s that rewarded drug makers for conducting clinical studies involving children. Among the incentives for cooperating companies was a possible six-month extension of protection from generic competition after a

GSK in weekend talks to buy Human Genome: sources

(Reuters) – GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the U.S. biotech company for three months, sources familiar with the situation said on Sunday.The British pharmaceutical giant could sweeten its pr

PMAC 2016 Side Event (SE 014): Advanced Workshop in Methods for HTA

PMAC 2016 Side Event (SE 014): Advanced Workshop in Methods for HTAThe methods of HTA have developed rapidly in the last decade. This is particularly the case in assessing the cost-effectiveness of interventions using modelling methods and in undertaking uncertainty analysis to guide decisions. Deci
10 / Page